Replies to post #22579 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT reinstated 2020 EPS guidance with a floor of $3.25 (non-GAAP); there is no ceiling.

[DewDiligence]

ABT 3Q20 Results by Business Segment

 
                  %Corp      YoY Growth  
 Segment          Sales   (const currency)  
 Medical devices*  36%        +3%  
 Diagnostics       30%       +39%  
 Nutrition         22%        +4%  
 Drugs†            12%        -3%

COVID-19 testing boosted the diagnostics segment, while the medical-devices segment bounced back from a COVID-related dip in 2Q20.

62% of overall sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.